PLAUR and cancer: MV-CD46-muPA, a dual-targeted oncolytic MV that simultaneously targets murine stromal (via uPAR) and human cancer cells (via CD46), markedly enhances antitumour effects on the HT-29 tumour model compared to CD46-targeted MV alone.